See more : Hengdeli Holdings Limited (3389.HK) Income Statement Analysis – Financial Results
Complete financial analysis of PTC Therapeutics, Inc. (PTCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PTC Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- EYEFI Group Technologies Inc. (EGTTF) Income Statement Analysis – Financial Results
- Regency Investments Limited (REGENCY.BO) Income Statement Analysis – Financial Results
- China Television Company, Ltd. (9928.TW) Income Statement Analysis – Financial Results
- Fortress Transportation and Infrastructure Investors LLC (FTAI-PC) Income Statement Analysis – Financial Results
- Platinum Capital Limited (PMC.AX) Income Statement Analysis – Financial Results
PTC Therapeutics, Inc. (PTCT)
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 937.82M | 698.80M | 538.59M | 380.77M | 306.98M | 264.73M | 194.39M | 82.71M | 36.77M | 22.96M | 31.33M | 28.78M | 98.96M |
| Cost of Revenue | 65.49M | 44.68M | 32.33M | 18.94M | 12.14M | 12.67M | 4.58M | 117.63M | 121.82M | 79.84M | 54.88M | -5.17M | 0.00 |
| Gross Profit | 872.34M | 654.12M | 506.27M | 361.82M | 294.85M | 252.06M | 189.82M | -34.93M | -85.05M | -56.88M | -23.55M | 33.95M | 98.96M |
| Gross Profit Ratio | 93.02% | 93.61% | 94.00% | 95.03% | 96.05% | 95.21% | 97.65% | -42.23% | -231.33% | -247.68% | -75.17% | 117.95% | 100.00% |
| Research & Development | 666.56M | 651.50M | 540.68M | 477.64M | 257.45M | 171.98M | 117.46M | 117.63M | 121.82M | 79.84M | 54.88M | 46.14M | 58.68M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 153.55M | 121.27M | 97.13M | 82.08M | 44.82M | 25.22M | 14.62M | 16.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 332.54M | 326.00M | 285.77M | 245.16M | 202.54M | 153.55M | 121.27M | 97.13M | 82.08M | 44.82M | 25.22M | 14.62M | 16.15M |
| Other Expenses | 0.00 | 116.55M | 54.75M | 36.89M | 27.65M | 129.00K | -1.28M | -1.21M | -465.00K | -213.00K | 37.51K | 1.78M | 461.36K |
| Operating Expenses | 1.31B | 1.09B | 881.21M | 759.70M | 487.64M | 348.41M | 254.11M | 214.76M | 203.90M | 122.38M | 76.72M | 55.59M | 68.38M |
| Cost & Expenses | 1.29B | 1.14B | 913.54M | 778.64M | 499.78M | 361.08M | 258.68M | 214.76M | 203.90M | 122.38M | 76.72M | 55.59M | 68.38M |
| Interest Income | 0.00 | 90.87M | 86.02M | 56.35M | 12.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 129.18M | 90.87M | 86.02M | 56.35M | 12.49M | 12.55M | 12.09M | 8.28M | 2.37M | 1.18M | 0.00 | 0.00 | 2.44M |
| Depreciation & Amortization | 236.59M | 128.84M | 71.52M | 49.58M | 36.06M | 26.09M | 17.68M | 3.29M | 2.88M | 2.24M | 2.40M | 2.70M | 2.87M |
| EBITDA | -330.34M | -367.78M | -374.44M | -297.00M | -191.38M | -89.47M | -46.61M | -128.77M | -164.25M | -97.18M | -43.00M | -24.10M | 33.45M |
| EBITDA Ratio | -35.22% | -53.32% | -70.20% | -59.83% | -38.04% | -20.45% | -25.16% | -159.67% | -454.58% | -432.93% | -136.85% | -83.76% | 33.80% |
| Operating Income | -349.40M | -439.93M | -374.94M | -397.88M | -192.80M | -115.69M | -64.29M | -132.06M | -167.13M | -99.41M | -45.40M | -26.81M | 30.58M |
| Operating Income Ratio | -37.26% | -62.95% | -69.62% | -104.49% | -62.80% | -43.70% | -33.07% | -159.67% | -454.58% | -432.93% | -144.92% | -93.15% | 30.90% |
| Total Other Income/Expenses | -346.71M | -147.56M | -143.40M | -59.36M | -47.13M | -12.43M | -13.37M | -9.48M | -2.83M | 967.00K | -6.18M | 573.00K | -1.98M |
| Income Before Tax | -696.11M | -587.49M | -518.34M | -402.93M | -239.93M | -128.11M | -77.67M | -141.54M | -169.96M | -98.45M | -51.57M | -26.24M | 28.60M |
| Income Before Tax Ratio | -74.23% | -84.07% | -96.24% | -105.82% | -78.16% | -48.39% | -39.95% | -171.14% | -462.28% | -428.72% | -164.63% | -91.16% | 28.90% |
| Income Tax Expense | -69.51M | -28.47M | 5.56M | 35.23M | 11.65M | -29.00K | 1.34M | 569.00K | 485.00K | -4.69M | 6.21M | 1.21M | -2.31M |
| Net Income | -626.60M | -559.02M | -523.90M | -438.16M | -251.58M | -128.08M | -79.00M | -142.11M | -170.45M | -93.75M | -51.57M | -26.24M | 30.90M |
| Net Income Ratio | -66.81% | -80.00% | -97.27% | -115.07% | -81.95% | -48.38% | -40.64% | -171.83% | -463.60% | -408.28% | -164.63% | -91.16% | 31.23% |
| EPS | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -4.02 | -1.85 | 0.00 |
| EPS Diluted | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 | -4.02 | -1.11 | 0.00 |
| Weighted Avg Shares Out | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.11M | 34.04M | 33.62M | 31.57M | 12.82M | 14.19M | 14.19M |
| Weighted Avg Shares Out (Dil) | 74.84M | 71.73M | 70.47M | 66.03M | 58.86M | 46.58M | 39.18M | 34.04M | 33.63M | 31.57M | 12.83M | 23.68M | 23.68M |
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy
PTC Therapeutics price target raised to $56 from $45 at Barclays
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
PTC Therapeutics discontinues development of ALS drug after trial failure
Source: https://incomestatements.info
Category: Stock Reports